<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340144</url>
  </required_header>
  <id_info>
    <org_study_id>IIS-000112</org_study_id>
    <nct_id>NCT01340144</nct_id>
  </id_info>
  <brief_title>Evaluation of Patellar Crepitus Following Total Knee Arthroplasty</brief_title>
  <official_title>Evaluation of Patellar Crepitus Following PFC Sigma vs. PFC Sigma HP Total Knee Arthroplasty: Does Femoral Component Design Make a Difference?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado Joint Replacement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DePuy Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Colorado Joint Replacement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analyze clinical data for a group of subjects implanted with a new surgical device designed
      to reduce the incidence of patellar crepitus following PCL-substituting TKA and compare that
      to a control group of subjects implanted with a TKA design known to have an incidence of
      patellar crepitus of approximately 5%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patellar crepitus and clunk following posterior cruciate substituting total knee arthroplasty
      is a persistent problem with a reported incidence as high as 14%. The development of this
      complication necessitates additional surgery in some patients. Numerous etiologies have been
      reported including design of the femoral component. Due to a higher than desired incidence of
      patellar crepitus with the PFC Sigma PS TKA, design modifications of the trochlear groove of
      the femoral component were introduced with the release of the PFC Sigma HP PS femoral
      component. The purpose of the proposed study is to evaluate the incidence of patellar
      crepitus after posterior cruciate substituting TKA utilizing the PFC Sigma vs. the PFC Sigma
      HP PS femoral components.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate for the Incidence of Patellar Crepitus Requiring Non-operative vs. Operative Treatment of Both the Study and Control Groups at a Minimum of 12 Months Following the TKA (Total Knee Arthroplasty) Procedure in Each Subject.</measure>
    <time_frame>Two years after TKA (Total Knee Arthroplasty) procedure</time_frame>
    <description>The incidence of patellar crepitus and clunk will be statistically compared between the study (PFC Sigma HP PS TKA) and control (PFC Sigma PS TKA groups). Based on a strength analysis to determine a theoretical reduction in the incidence of patellar crepitus from 5% to 2%, a study group of 625 subjects in both the control and study ggroups will be required. Each group will also be statistically analyzed using the following variables: overall crepitus incidence, incidence of crepitus requiring only non-operative treatment vs. those requiring operative treatment to manage this complication.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1250</enrollment>
  <condition>Total Knee Replacement</condition>
  <arm_group>
    <arm_group_label>PFC Sigma PS TKA</arm_group_label>
    <description>one group received primary TKA using the PFC Sigma PS TKA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PFC Sigma HP PS TKA</arm_group_label>
    <description>One group received primary TKA using the PFC Sigma HP PS TKA.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Colorado Joint replacement clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects that received primary total knee replacement

        Exclusion Criteria:

          -  Did not return for follow - up appointments Required any post operative manipulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Porter Adventist Hospital</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <results_first_submitted>February 19, 2015</results_first_submitted>
  <results_first_submitted_qc>February 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2015</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>total knee replacement</keyword>
  <keyword>patellar crepitus</keyword>
  <keyword>Replacement of knee joint</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PFC Sigma PS TKA (Total Knee Arthroplasty)</title>
          <description>One group received primary TKA using the PFC Sigma PS TKA</description>
        </group>
        <group group_id="P2">
          <title>PFC Sigma HP PS TKA (Total Knee Arthroplasty)</title>
          <description>One group received primary TKA using the PFC Sigma HP PS TKA.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="625"/>
                <participants group_id="P2" count="625"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="553"/>
                <participants group_id="P2" count="567"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PFC Sigma PS TKA (Total Knee Arthroplasty)</title>
          <description>One group received primary TKA using the PFC Sigma PS TKA</description>
        </group>
        <group group_id="B2">
          <title>PFC Sigma HP PS TKA (Total Knee Arthoplasty)</title>
          <description>One group received primary TKA using the PFC Sigma HP PS TKA.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="625"/>
            <count group_id="B2" value="625"/>
            <count group_id="B3" value="1250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" lower_limit="46.9" upper_limit="84.3"/>
                    <measurement group_id="B2" value="65.6" lower_limit="47.3" upper_limit="83.9"/>
                    <measurement group_id="B3" value="65.6" lower_limit="46.9" upper_limit="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                    <measurement group_id="B2" value="352"/>
                    <measurement group_id="B3" value="702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="625"/>
                    <measurement group_id="B2" value="625"/>
                    <measurement group_id="B3" value="1250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate for the Incidence of Patellar Crepitus Requiring Non-operative vs. Operative Treatment of Both the Study and Control Groups at a Minimum of 12 Months Following the TKA (Total Knee Arthroplasty) Procedure in Each Subject.</title>
        <description>The incidence of patellar crepitus and clunk will be statistically compared between the study (PFC Sigma HP PS TKA) and control (PFC Sigma PS TKA groups). Based on a strength analysis to determine a theoretical reduction in the incidence of patellar crepitus from 5% to 2%, a study group of 625 subjects in both the control and study ggroups will be required. Each group will also be statistically analyzed using the following variables: overall crepitus incidence, incidence of crepitus requiring only non-operative treatment vs. those requiring operative treatment to manage this complication.</description>
        <time_frame>Two years after TKA (Total Knee Arthroplasty) procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma PS TKA (Total Knee Arthroplasty)</title>
            <description>One group received primary TKA using the PFC Sigma PS TKA</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma HP PS TKA (Total Knee Arthroplasty)</title>
            <description>One group received primary TKA using the PFC Sigma HP PS TKA.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate for the Incidence of Patellar Crepitus Requiring Non-operative vs. Operative Treatment of Both the Study and Control Groups at a Minimum of 12 Months Following the TKA (Total Knee Arthroplasty) Procedure in Each Subject.</title>
          <description>The incidence of patellar crepitus and clunk will be statistically compared between the study (PFC Sigma HP PS TKA) and control (PFC Sigma PS TKA groups). Based on a strength analysis to determine a theoretical reduction in the incidence of patellar crepitus from 5% to 2%, a study group of 625 subjects in both the control and study ggroups will be required. Each group will also be statistically analyzed using the following variables: overall crepitus incidence, incidence of crepitus requiring only non-operative treatment vs. those requiring operative treatment to manage this complication.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Crepitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic Crepitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Operative Crepitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PFC Sigma PS TKA (Total Knee Arthroplasty)</title>
          <description>One group received primary TKA using the PFC Sigma PS TKA</description>
        </group>
        <group group_id="E2">
          <title>PFC Sigma HP PS TKA (Total Knee Arthroplasty)</title>
          <description>One group received primary TKA using the PFC Sigma HP PS TKA.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Cause of Death: MI</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Unknown cause</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="625"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Failed total knee due to infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Cause of death: sepsis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Failed total knee due to arthrofibrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Failed TKA due to chronic patellofemoral and mild tibiofemoral instability</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Dehiscence</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Chronic lateral patellar irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Hemarthrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Arthrofibrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="625"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Below knee amputation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Total hip replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Hip dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Femoral fracture</sub_title>
                <description>Nondisplaced femoral neck fracture</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Failed TKA</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Failed TKA due to quadriceps tendon rupture</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Conralateral TKA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Lumbar stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Hetrotrophic bone formation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Achilles tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Colon cancer with liver metastases</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Cerebellar tumor, esophageal cancer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Bladder cancer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Lung cancer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Lung cancer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peroneal nerve entrapment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Cause of death: Pneumonia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="625"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond Kim, MD</name_or_title>
      <organization>Colorado Joint Replacement</organization>
      <phone>720-524-1367</phone>
      <email>raymondkim@ccentura.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

